Efficacy and Tolerance of JAK Inhibitors in ATU for Atopic Dermatitis

A Study to Evaluate the Efficacy and Safety of AK120 in Subjects With Moderate to Severe Atopic Dermatitis

NCT06700499 ·Status: COMPLETED ·Phase: PHASE2

An Observational Study to Assess Change in Disease Activity and Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in Real World

NCT05669794 ·Status: ACTIVE_NOT_RECRUITING

Efficacy and Safety Trial of ALK-depot SQ Mites in Subjects With Atopic Dermatitis

NCT00310492 ·Status: COMPLETED ·Phase: PHASE3

French Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (AD)

NCT06837454 ·Status: RECRUITING

Clinical Study of Jaktinib in the Treatment of Patients With Moderate and Severe Atopic Dermatitis

NCT04539639 ·Status: COMPLETED ·Phase: PHASE2

Real-world Effectiveness Study of Long-term Treatment With Dupilumab in Participants ≥6 Years With Atopic Dermatitis

NCT06039241 ·Status: RECRUITING

A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis

NCT05999799 ·Status: TERMINATED ·Phase: PHASE2

Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis

NCT05990725 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

NCT06832618 ·Status: RECRUITING ·Phase: PHASE3

A Long-term Data Collection Study of Participants in France Aged 6 Years Old or More With Atopic Dermatitis Receiving Dupilumab

NCT06169527 ·Status: ACTIVE_NOT_RECRUITING

A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

NCT05601882 ·Status: COMPLETED ·Phase: PHASE3

A Study to Assess the Efficacy and Safety of CMK389 in Patients With Moderate to Severe Atopic Dermatitis.

NCT04836858 ·Status: COMPLETED ·Phase: PHASE2

Results in Real Clinical Practice of Treatment of Moderate-severe Atopic Dermatitis

NCT05078294 ·Status: UNKNOWN

A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis

NCT05507580 ·Status: COMPLETED ·Phase: PHASE4

A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

NCT06807281 ·Status: RECRUITING ·Phase: PHASE3

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis

NCT03646604 ·Status: COMPLETED ·Phase: PHASE1

Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

NCT03720470 ·Status: COMPLETED ·Phase: PHASE3

Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

NCT04345367 ·Status: COMPLETED ·Phase: PHASE3

A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to <18 Years With Atopic Dermatitis (Eczema)

NCT02407756 ·Status: COMPLETED ·Phase: PHASE2

A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic Dermatitis

NCT05526222 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

NCT04875169 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

NCT03568318 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Efficacy and Safety Study of QAW039 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis.

NCT01785602 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

NCT06241118 ·Status: RECRUITING ·Phase: PHASE3

A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis

NCT06238817 ·Status: COMPLETED ·Phase: PHASE3